Supernus Pharmaceuticals (SUPN) said Monday the US Food and Drug Administration has cleared a label update for qelbree, a treatment for attention-deficit/hyperactivity disorder, or ADHD.

The updated label describes the drug's "partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter," which highlights the treatment's "multimodal pharmacodynamic profile," the biopharmaceutical company said.

The revised label also includes new lactation data for breastfeeding women with ADHD "showing that the transfer of Qelbree into breastmilk is low," Supernus said.

The drug is approved for use by people ages 6 years and older with ADHD, the company said.

SUPN shares were up 1.8% in early trading.

Price: 38.85, Change: +0.30, Percent Change: +0.78